{"id":"bosentan-and-sildenafil","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL957","moleculeType":"Small molecule","molecularWeight":"551.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bosentan is an endothelin receptor antagonist that blocks the vasoconstrictive effects of endothelin-1 in pulmonary vessels. Sildenafil is a phosphodiesterase-5 inhibitor that increases cyclic GMP levels, promoting vasodilation. The combination targets complementary pathways in pulmonary hypertension pathophysiology to achieve synergistic hemodynamic improvement.","oneSentence":"Bosentan blocks endothelin-1 receptors while sildenafil inhibits phosphodiesterase-5, together reducing pulmonary vascular resistance and improving right ventricular function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:25.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT04039464","phase":"PHASE3","title":"Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-08-01","conditions":"Pediatric Pulmonary Hypertension","enrollment":28},{"nctId":"NCT05039086","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-09-01","conditions":"Pulmonary Arterial Hypertension","enrollment":13021},{"nctId":"NCT00433329","phase":"PHASE4","title":"Combination Therapy in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2007-03","conditions":"Pulmonary Arterial Hypertension","enrollment":100},{"nctId":"NCT00303459","phase":"PHASE4","title":"Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2006-05","conditions":"Pulmonary Arterial Hypertension","enrollment":334},{"nctId":"NCT00302211","phase":"PHASE3","title":"The \"VISION\" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2006-02-01","conditions":"Pulmonary Hypertension","enrollment":67},{"nctId":"NCT06317805","phase":"PHASE4","title":"Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients","status":"RECRUITING","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2023-12-06","conditions":"Pulmonary Arterial Hypertension","enrollment":110},{"nctId":"NCT04770155","phase":"EARLY_PHASE1","title":"Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1","status":"TERMINATED","sponsor":"University of Mississippi Medical Center","startDate":"2021-05-27","conditions":"Vascular Function, Racial Disparity","enrollment":8},{"nctId":"NCT02565030","phase":"","title":"Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-02","conditions":"Chronic Thromboembolic Pulmonary Hypertension, Idiopathic Pulmonary Arterial Hypertension","enrollment":1200},{"nctId":"NCT01392469","phase":"PHASE3","title":"Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04-20","conditions":"Pulmonary Arterial Hypertension","enrollment":21},{"nctId":"NCT00323297","phase":"PHASE4","title":"Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-09","conditions":"Pulmonary Arterial Hypertension","enrollment":105},{"nctId":"NCT04379180","phase":"","title":"Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2020-04-26","conditions":"Persistent Pulmonary Hypertension of the Newborn","enrollment":500},{"nctId":"NCT01548950","phase":"NA","title":"Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2011-09","conditions":"Congenital Heart Disease, Pulmonary Arterial Hypertension","enrollment":50},{"nctId":"NCT02484807","phase":"","title":"Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2015-05","conditions":"Pulmonary Arterial Hypertension","enrollment":125},{"nctId":"NCT01247116","phase":"","title":"First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2009-12","conditions":"Hypertension, Pulmonary","enrollment":12},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT03236818","phase":"PHASE4","title":"Goal Oriented Strategy to Preserve Ejection Fraction Trial","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-05","conditions":"Pulmonary Arterial Hypertension","enrollment":30},{"nctId":"NCT03053739","phase":"PHASE4","title":"To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-12","conditions":"Associated Pulmonary Arterial Hypertension","enrollment":50},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT01836263","phase":"","title":"Prevention and Treatment of Digital Ulcers in Systemic Sclerosis","status":"UNKNOWN","sponsor":"marco matucci cerinic","startDate":"2013-04","conditions":"Systemic Sclerosis, Ulcer","enrollment":420},{"nctId":"NCT01449253","phase":"PHASE4","title":"Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2011-08","conditions":"Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia","enrollment":60},{"nctId":"NCT00478296","phase":"","title":"Pulmonary Hypertension in Trisomy 21 Patients","status":"COMPLETED","sponsor":"Children's Healthcare of Atlanta","startDate":"2004-10","conditions":"Congenital Disorders","enrollment":1},{"nctId":"NCT00303004","phase":"PHASE3","title":"Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2006-03","conditions":"Eisenmenger Syndrome","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bosentan and Sildenafil","genericName":"Bosentan and Sildenafil","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bosentan blocks endothelin-1 receptors while sildenafil inhibits phosphodiesterase-5, together reducing pulmonary vascular resistance and improving right ventricular function. Used for Pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}